PNPLA3 and IL 28B signature for predicting susceptibility to chronic hepatitis C infection and fibrosis progression

References

• Bochud, P.-Y., et al., 2012. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 55(2), 384–394.
   PubMed Web of Science ®Google Scholar
• Davis, G.L., et al., 2010. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology, 138(2), 513–521.
   PubMed Web of Science ®Google Scholar
• Domagalski, K., et al., 2013. Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. European journal of clinical microbiology & infectious diseases, 32(6), 745–754.
   PubMed Web of Science ®Google Scholar
• Dongiovanni, P., Romeo, S., and Valenti, L., 2015. Genetic factors in the pathogenesis of nonalcoholic fatty liver and steatohepatitis. Biomed research international, 2015, 460190.
   PubMed Web of Science ®Google Scholar
• Echeverria, N., Chiodi, D., and Lopez, P., 2018. IL28B gene polymorphism rs12979860, but not rs8099917, contributes to the occurrence of chronic HCV infection in Uruguayan patients. Virology journal, 15, 40.
   PubMed Web of Science ®Google Scholar
• Estrabaud, E., et al., 2012. Genomics and HCV infection: progression of fibrosis and treatment response. Journal of hepatology, 57(5), 1110–1125.
   PubMed Web of Science ®Google Scholar
• Ge, D., et al., 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461(7262), 399–401.
   PubMed Web of Science ®Google Scholar
• Georgel, P., et al., 2010. Virus-host interactions in hepatitis C virus infection: implications for molecular pathogenesis and antiviral strategies. Trends in molecular medicine, 16(6), 277–286.
   PubMed Web of Science ®Google Scholar
• Gower, E., et al., 2014. Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of hepatology, 61(1), S45–S57.
   PubMedGoogle Scholar
• He, S., et al., 2010. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. Journal of biological chemistry, 285(9), 6706–6715.
   PubMed Web of Science ®Google Scholar
• Hoofnagle, J.H., 2002. Course and outcome of hepatitis C. Hepatology, 36, S21–S29.
   PubMed Web of Science ®Google Scholar
• Huang, C.-I., et al., 2018. Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. Medicine, 97(10), e9782.
   PubMed Web of Science ®Google Scholar
• Kandeel, A., et al., 2017. The prevalence of hepatitis C virus infection in Egypt 2015: implications for future policy on prevention and treatment. Liver international, 37(1), 45–53.
   PubMed Web of Science ®Google Scholar
• Kawaguchi, T., et al., 2012. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. Plos one, 7(6), e38322.
   PubMed Web of Science ®Google Scholar
• Khattab, M.A., et al., 2011. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. Journal of hepatology, 54(6), 1250–1262.
   PubMed Web of Science ®Google Scholar
• Kitamoto, T., et al., 2013. Genome-wide scan revealed that polymorphisms in the PNPLA3, SAMM50, and PARVB genes are associated with development and progression of nonalcoholic fatty liver disease in Japan. Human genetics, 132(7), 783–792.
   PubMed Web of Science ®Google Scholar
• Kitamoto, T., et al., 2014. Targeted next-generation sequencing and fine linkage disequilibrium mapping reveals association of PNPLA3 and PARVB with the severity of nonalcoholic fatty liver disease. Journal of human genetics, 59(5), 241–246.
   PubMed Web of Science ®Google Scholar
• Kurosaki, M., et al., 2011. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. Journal of hepatology, 54(3), 439–448.
   PubMed Web of Science ®Google Scholar
• Lavanchy, D., 2011. Evolving epidemiology of hepatitis C virus. Clinical microbiology and infection, 17(2), 107–115.
   PubMed Web of Science ®Google Scholar
• Layden, J.E., et al., 2014. Association of genetic variants with rapid fibrosis: progression after liver transplantation for hepatitis C. Transplantation, 97(10), 1072–1078.
   PubMed Web of Science ®Google Scholar
• Lindh, M., et al., 2011. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. Journal of viral hepatitis, 18(7), e325–e331.
   PubMed Web of Science ®Google Scholar
• Manchiero, C., et al., 2017. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. BMC infectious diseases, 17(1), 780.
   PubMedGoogle Scholar
• Marabita, F., et al., 2011. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology, 54(4), 1127–1134.
   PubMed Web of Science ®Google Scholar
• Miyashita, M., et al., 2012. Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. Journal of viral hepatitis, 19(9), 608–614.
   PubMed Web of Science ®Google Scholar
• Mohamoud, Y.A., et al., 2013. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC infectious diseases, 13(1), 288.
   PubMedGoogle Scholar
• Mohd, H.K., Groeger, J., and Flaxman, A.D., 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology, 57, 1333–1342.
   PubMed Web of Science ®Google Scholar
• Noureddin, M., et al., 2013. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology, 58(5), 1548–1557.
   PubMed Web of Science ®Google Scholar
• O’Connor, K.S., Read, S.A., and Wang, M., 2016. IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection. Genes & immunity, 17, 328–334.
   PubMed Web of Science ®Google Scholar
• Pawlotsky, J.M., 2011. Has genetics eradicated the good old predictors of hepatitis C treatment response? Clinics and research in hepatology and gastroenterology, 35(3), 157–158.
   PubMed Web of Science ®Google Scholar
• Rauch, A., et al., 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138(4), 1338–1345.
   PubMed Web of Science ®Google Scholar
• Rehermann, B., 2009. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. Journal of clinical investigation, 119(7), 1745–1754.
   PubMed Web of Science ®Google Scholar
• Rembeck, K., and Lagging, M., 2015. Impact of IL28B, ITPA and PNPLA3 genetic variants on therapeutic outcome and progression of hepatitis C virus infection. Pharmacogenomics, 16(10), 1179–1188.
   PubMed Web of Science ®Google Scholar
• Romeo, S., et al., 2008. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature genetics, 40(12), 1461–1465.
   PubMed Web of Science ®Google Scholar
• Rotman, Y., et al., 2010. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology, 52(3), 894–903.
   PubMed Web of Science ®Google Scholar
• Salameh, H., et al., 2016. PNPLA3 as a genetic determinant of risk for and severity of non-alcoholic fatty liver disease spectrum. Journal of clinical and translational hepatology, 4(3), 175–191.
   PubMed Web of Science ®Google Scholar
• Scheiner, B., et al., 2015. The Impact of PNPLA3 rs738409 SNP on liver fibrosis progression, portal hypertension and hepatic steatosis in HIV/HCV coinfection. PLoS one, 10(11), e0143429
   PubMed Web of Science ®Google Scholar
• Seeff, L.B., 2002. Natural history of chronic hepatitis C. Hepatology, 36, S35–S46.
   PubMed Web of Science ®Google Scholar
• Sibbing, B., and Nattermann, J., 2011. Hepatitis C virus infection and genetic susceptibility to therapy. Journal of gastrointestinal and liver diseases, 20(4), 397–406.
   PubMed Web of Science ®Google Scholar
• Singal, A.G., et al., 2014. The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis. American journal of gastroenterology, 109(3), 325–334.
   PubMed Web of Science ®Google Scholar
• Stanaway, J.D., et al., 2016. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. The lancet, 388(10049), 1081–1088.
   PubMed Web of Science ®Google Scholar
• Stattermayer, A.F., Rutter, K., and Beinhardt, S., 2012. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. Journal of hepatology, 57, 492–498.
   PubMed Web of Science ®Google Scholar
• Stattermayer, A.F., Rutter, K., and Beinhardt, S., 2014. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. Liver international, 34, 388–395.
   PubMed Web of Science ®Google Scholar
• Stattermayer, A.F., Traussnigg, S., and Aigner, E., 2017. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. Journal of trace elements in medicine and biology, 39, 100–107.
   PubMed Web of Science ®Google Scholar
• Stickel, F., et al., 2011. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology, 53(1), 86–95.
   PubMed Web of Science ®Google Scholar
• Suppiah, V., et al., 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature genetics, 41(10), 1100–1104.
   PubMed Web of Science ®Google Scholar
• Tamaki, N., et al., 2015. Genetic polymorphisms of IL28B and PNPLA3 are predictive for HCV related rapid fibrosis progression and identify patients who require urgent antiviral treatment with new regimens. PLoS one, 10(9), e0137351.
   PubMed Web of Science ®Google Scholar
• Tanaka, Y., et al., 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature genetics, 41(10), 1105–1109.
   PubMed Web of Science ®Google Scholar
• Tian, C., et al., 2010. Variant in PNPLA3 is associated with alcoholic liver disease. Nature genetics, 42(1), 21–23.
   PubMed Web of Science ®Google Scholar
• Trepo, E., Pradat, P., and Potthoff, A., 2011. Impact of patatin-like phospholipase-3 (rs738409 C > G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology, 54, 60–69.
   PubMed Web of Science ®Google Scholar
• Valenti, L., et al., 2010. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 51(4), 1209–1217.
   PubMed Web of Science ®Google Scholar
• Valenti, L., et al., 2011. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C. Hepatology, 53(3), 791–799.
   PubMed Web of Science ®Google Scholar
• Valenti, L., et al., 2012. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Alimentary pharmacology & therapeutics, 35(12), 1434–1442.
   PubMed Web of Science ®Google Scholar
• Venegas, M., Villanueva, R.A., and Gonzalez, K., 2011. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World journal of gastroenterology, 17(31), 3636–3639.
   PubMed Web of Science ®Google Scholar
• Wong, G.L.-H., et al., 2015. Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus. Journal of gastroenterology and hepatology, 30(6), 1040–1048.
   PubMed Web of Science ®Google Scholar
• Zakaria, Z.A., Knapp, S., and Hashem, M., 2018. Interleukin 28A. rs12980602 and interleukin 28B. rs8103142 genotypes could be protective against HCV infection among Egyptians. Immunologic research, 67, 1–11.
   Web of Science ®Google Scholar